MarketCap
Facebook
X
TelegramAnnual report 2022
added 08-16-2022
Global Cord Blood Corporation Total Assets 2011-2025 | CO
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Global Cord Blood Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.53 B | 7.91 B | 7.22 B | 6.55 B | 5.84 B | 5.18 B | 4.69 B | 4.12 B | 3.63 B | 2.99 B | 1.82 B | 1.56 B |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.53 B | 1.56 B | 5 B |
Quarterly Total Assets Global Cord Blood Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 8.53 B | - | 8.26 B | - | 7.91 B | - | 7.57 B | - | 7.22 B | - | 6.95 B | - | 6.55 B | - | 6.2 B | - | 5.84 B | - | 5.57 B | - | 5.18 B | - | 4.85 B | - | 4.69 B | - | 4.37 B | - | 4.11 B | - | 3.87 B | - | 3.63 B | - | 3.29 B | 3.11 B | 2.99 B | - | 2.42 B | 2.27 B | 1.82 B | 1.67 B | 1.6 B | - | 1.56 B |
All numbers in CNY currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.53 B | 1.56 B | 4.69 B |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
94.3 M | $ 17.27 | 1.8 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 15.82 | 0.44 % | $ 170 M |  China |
 |
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
76.7 M | $ 1.55 | -4.63 % | $ 1.97 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M |  Britain |
 |
DarioHealth Corp.
DRIO
|
96.4 M | $ 12.14 | 2.1 % | $ 344 M | Israel |
 |
DexCom
DXCM
|
6.26 B | $ 65.83 | -1.69 % | $ 25.4 B | USA |
 |
Castle Biosciences
CSTL
|
531 M | $ 39.06 | 1.11 % | $ 1.08 B | USA |
 |
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Exact Sciences Corporation
EXAS
|
5.93 B | $ 101.64 | 0.14 % | $ 18.8 B | USA |
 |
Danaher Corporation
DHR
|
77.5 B | $ 227.72 | 0.54 % | $ 166 B | USA |
 |
Fulgent Genetics
FLGT
|
1.22 B | $ 27.0 | -0.52 % | $ 816 M | USA |
 |
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
467 M | $ 19.98 | -2.82 % | $ 1.07 B | USA |
 |
Celcuity
CELC
|
245 M | $ 101.67 | -3.4 % | $ 4.01 B | USA |
 |
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | USA |
 |
Anixa Biosciences
ANIX
|
21.6 M | $ 3.3 | -7.82 % | $ 105 K | USA |
 |
Co-Diagnostics
CODX
|
95.3 M | $ 0.29 | -14.47 % | $ 8.51 M | USA |
 |
IQVIA Holdings
IQV
|
26.9 B | $ 222.75 | 0.24 % | $ 40.4 B | USA |
 |
Guardant Health
GH
|
1.49 B | $ 103.7 | 1.6 % | $ 12.7 B | USA |
 |
Aspira Women's Health
AWH
|
17.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
6.3 B | $ 134.4 | -0.35 % | $ 21.4 B | USA |
 |
Charles River Laboratories International
CRL
|
7.53 B | $ 197.62 | 2.4 % | $ 10.2 B | USA |
 |
Quotient Limited
QTNT
|
220 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Mettler-Toledo International
MTD
|
3.24 B | $ 1 410.02 | 1.15 % | $ 29.9 B | Schweiz |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 183.96 | 0.79 % | $ 20.4 B | USA |
 |
NeoGenomics
NEO
|
1.64 B | $ 12.03 | 1.48 % | $ 1.52 B | USA |
 |
Neogen Corporation
NEOG
|
3.44 B | $ 6.85 | -0.22 % | $ 1.49 B | USA |
|
Biodesix
BDSX
|
97.2 M | $ 7.63 | -2.8 % | $ 989 M | USA |
 |
Myriad Genetics
MYGN
|
1.03 B | $ 7.04 | -2.36 % | $ 638 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 262.89 | -0.48 % | $ 22.1 B | USA |
 |
ICON Public Limited Company
ICLR
|
16.9 B | $ 184.38 | -1.18 % | $ 15.2 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
3.29 B | $ 698.77 | -0.77 % | $ 57.6 B | USA |
 |
Lantheus Holdings
LNTH
|
1.98 B | $ 66.4 | -0.33 % | $ 4.59 B | USA |
 |
Agilent Technologies
A
|
10.7 B | $ 140.3 | 0.46 % | $ 42.7 B | USA |
 |
Biomerica
BMRA
|
5.94 M | $ 2.48 | -2.65 % | $ 5.7 M | USA |
 |
Bioventus
BVS
|
811 M | $ 7.49 | -0.86 % | $ 469 M | USA |
 |
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M | Israel |
 |
Pacific Biosciences of California
PACB
|
1.75 B | $ 2.13 | 0.24 % | $ 540 M | USA |
 |
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | Israel |